| __timestamp | HUTCHMED (China) Limited | Pharming Group N.V. |
|---|---|---|
| Wednesday, January 1, 2014 | 26684000 | 4042025 |
| Thursday, January 1, 2015 | 29829000 | 5279557 |
| Friday, January 1, 2016 | 39578000 | 8073913 |
| Sunday, January 1, 2017 | 43277000 | 44864073 |
| Monday, January 1, 2018 | 48645000 | 53488904 |
| Tuesday, January 1, 2019 | 52934000 | 65896361 |
| Wednesday, January 1, 2020 | 61349000 | 69968267 |
| Friday, January 1, 2021 | 127125000 | 92047281 |
| Saturday, January 1, 2022 | 136106000 | 131819000 |
| Sunday, January 1, 2023 | 133175999 | 87501000 |
Unleashing insights
In the ever-evolving pharmaceutical landscape, understanding the financial strategies of key players is crucial. Over the past decade, HUTCHMED (China) Limited and Pharming Group N.V. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, HUTCHMED's SG&A expenses surged by nearly 400%, peaking in 2022. This growth reflects their aggressive expansion and market penetration strategies. In contrast, Pharming Group N.V. exhibited a more moderate increase of approximately 210% over the same period, with a notable spike in 2022, suggesting strategic investments in operational efficiency. The year 2021 marked a pivotal point for both companies, with HUTCHMED's expenses nearly doubling, while Pharming's expenses increased by 32%. These trends highlight the dynamic nature of the pharmaceutical industry and the diverse strategies companies employ to maintain competitive edges.
Eli Lilly and Company or HUTCHMED (China) Limited: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Pharming Group N.V.
Comparing SG&A Expenses: Novartis AG vs Pharming Group N.V. Trends and Insights
Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Pharming Group N.V. Trends and Insights
SG&A Efficiency Analysis: Comparing Jazz Pharmaceuticals plc and Pharming Group N.V.
Breaking Down SG&A Expenses: Pharming Group N.V. vs BioCryst Pharmaceuticals, Inc.
Comparing SG&A Expenses: Madrigal Pharmaceuticals, Inc. vs HUTCHMED (China) Limited Trends and Insights
Axsome Therapeutics, Inc. and HUTCHMED (China) Limited: SG&A Spending Patterns Compared
CymaBay Therapeutics, Inc. and HUTCHMED (China) Limited: SG&A Spending Patterns Compared
Amicus Therapeutics, Inc. and HUTCHMED (China) Limited: SG&A Spending Patterns Compared
HUTCHMED (China) Limited vs Supernus Pharmaceuticals, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: HUTCHMED (China) Limited vs Novavax, Inc.